Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict
Eur Urol
.
2017 Jan;71(1):6-7.
doi: 10.1016/j.eururo.2016.08.071.
Epub 2016 Sep 15.
Authors
Julie Steinestel
1
,
Christof Bernemann
2
,
Andres J Schrader
2
,
Jochen K Lennerz
3
Affiliations
1
Clinic of Urology, University Hospital Münster, Münster, Germany. Electronic address: julie.steinestel@ukmuenster.de.
2
Clinic of Urology, University Hospital Münster, Münster, Germany.
3
Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
PMID:
27641787
DOI:
10.1016/j.eururo.2016.08.071
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Male
Prostate-Specific Antigen*
Prostatic Neoplasms*
Substances
Prostate-Specific Antigen